RPRX vs. SYK: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at RPRX and SYK, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | RPRX | SYK |
|---|---|---|
| Company Name | Royalty Pharma plc | Stryker Corporation |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Pharmaceuticals | Health Care Equipment & Supplies |
| Market Capitalization | 23.01 billion USD | 138.01 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | June 16, 2020 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of RPRX and SYK by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | RPRX | SYK |
|---|---|---|
| 5-Day Price Return | 1.61% | 2.03% |
| 13-Week Price Return | 7.73% | -5.16% |
| 26-Week Price Return | 19.32% | -6.53% |
| 52-Week Price Return | 51.49% | -6.73% |
| Month-to-Date Return | 4.32% | 1.68% |
| Year-to-Date Return | 53.51% | 0.60% |
| 10-Day Avg. Volume | 5.43M | 2.03M |
| 3-Month Avg. Volume | 3.75M | 1.41M |
| 3-Month Volatility | 26.39% | 20.46% |
| Beta | 0.42 | 0.89 |
Profitability
Return on Equity (TTM)
RPRX
11.59%
Pharmaceuticals Industry
- Max
- 38.95%
- Q3
- 20.34%
- Median
- 11.59%
- Q1
- 3.32%
- Min
- -10.91%
RPRX’s Return on Equity of 11.59% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
SYK
13.92%
Health Care Equipment & Supplies Industry
- Max
- 29.82%
- Q3
- 15.54%
- Median
- 9.69%
- Q1
- 5.19%
- Min
- -7.98%
SYK’s Return on Equity of 13.92% is on par with the norm for the Health Care Equipment & Supplies industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
RPRX
32.55%
Pharmaceuticals Industry
- Max
- 39.07%
- Q3
- 19.28%
- Median
- 13.48%
- Q1
- 5.73%
- Min
- -8.86%
A Net Profit Margin of 32.55% places RPRX in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
SYK
12.07%
Health Care Equipment & Supplies Industry
- Max
- 24.65%
- Q3
- 14.10%
- Median
- 10.09%
- Q1
- 5.84%
- Min
- -6.13%
SYK’s Net Profit Margin of 12.07% is aligned with the median group of its peers in the Health Care Equipment & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
RPRX
65.22%
Pharmaceuticals Industry
- Max
- 45.58%
- Q3
- 24.35%
- Median
- 18.05%
- Q1
- 7.58%
- Min
- -11.88%
RPRX’s Operating Profit Margin of 65.22% is exceptionally high, placing it well above the typical range for the Pharmaceuticals industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.
SYK
15.04%
Health Care Equipment & Supplies Industry
- Max
- 31.34%
- Q3
- 18.36%
- Median
- 15.07%
- Q1
- 9.62%
- Min
- -0.13%
SYK’s Operating Profit Margin of 15.04% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | RPRX | SYK |
|---|---|---|
| Return on Equity (TTM) | 11.59% | 13.92% |
| Return on Assets (TTM) | 4.16% | 6.46% |
| Net Profit Margin (TTM) | 32.55% | 12.07% |
| Operating Profit Margin (TTM) | 65.22% | 15.04% |
| Gross Profit Margin (TTM) | -- | 64.59% |
Financial Strength
Current Ratio (MRQ)
RPRX
3.48
Pharmaceuticals Industry
- Max
- 5.45
- Q3
- 2.99
- Median
- 1.98
- Q1
- 1.29
- Min
- 0.78
RPRX’s Current Ratio of 3.48 is in the upper quartile for the Pharmaceuticals industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
SYK
1.85
Health Care Equipment & Supplies Industry
- Max
- 4.97
- Q3
- 2.92
- Median
- 2.12
- Q1
- 1.54
- Min
- 0.86
SYK’s Current Ratio of 1.85 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
RPRX
1.39
Pharmaceuticals Industry
- Max
- 1.79
- Q3
- 0.78
- Median
- 0.31
- Q1
- 0.08
- Min
- 0.00
RPRX’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 1.39. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
SYK
0.68
Health Care Equipment & Supplies Industry
- Max
- 1.62
- Q3
- 0.74
- Median
- 0.47
- Q1
- 0.15
- Min
- 0.00
SYK’s Debt-to-Equity Ratio of 0.68 is typical for the Health Care Equipment & Supplies industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
RPRX
4.70
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 10.15
- Q1
- 2.37
- Min
- -42.71
RPRX’s Interest Coverage Ratio of 4.70 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
SYK
14.59
Health Care Equipment & Supplies Industry
- Max
- 56.35
- Q3
- 24.86
- Median
- 9.84
- Q1
- 3.86
- Min
- -21.65
SYK’s Interest Coverage Ratio of 14.59 is positioned comfortably within the norm for the Health Care Equipment & Supplies industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | RPRX | SYK |
|---|---|---|
| Current Ratio (MRQ) | 3.48 | 1.85 |
| Quick Ratio (MRQ) | 3.48 | 0.94 |
| Debt-to-Equity Ratio (MRQ) | 1.39 | 0.68 |
| Interest Coverage Ratio (TTM) | 4.70 | 14.59 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
RPRX
1.67%
Pharmaceuticals Industry
- Max
- 6.72%
- Q3
- 3.48%
- Median
- 1.90%
- Q1
- 0.00%
- Min
- 0.00%
RPRX’s Dividend Yield of 1.67% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
SYK
0.92%
Health Care Equipment & Supplies Industry
- Max
- 4.36%
- Q3
- 1.87%
- Median
- 0.82%
- Q1
- 0.00%
- Min
- 0.00%
SYK’s Dividend Yield of 0.92% is consistent with its peers in the Health Care Equipment & Supplies industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
RPRX
49.36%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 85.87%
- Median
- 49.36%
- Q1
- 1.12%
- Min
- 0.00%
RPRX’s Dividend Payout Ratio of 49.36% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
SYK
43.09%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 67.77%
- Median
- 28.21%
- Q1
- 0.00%
- Min
- 0.00%
SYK’s Dividend Payout Ratio of 43.09% is within the typical range for the Health Care Equipment & Supplies industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | RPRX | SYK |
|---|---|---|
| Dividend Yield (TTM) | 1.67% | 0.92% |
| Dividend Payout Ratio (TTM) | 49.36% | 43.09% |
Valuation
Price-to-Earnings Ratio (TTM)
RPRX
29.52
Pharmaceuticals Industry
- Max
- 52.64
- Q3
- 29.89
- Median
- 20.77
- Q1
- 13.37
- Min
- 5.71
RPRX’s P/E Ratio of 29.52 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
SYK
46.83
Health Care Equipment & Supplies Industry
- Max
- 67.59
- Q3
- 41.41
- Median
- 33.11
- Q1
- 22.82
- Min
- 8.68
A P/E Ratio of 46.83 places SYK in the upper quartile for the Health Care Equipment & Supplies industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
Price-to-Sales Ratio (TTM)
RPRX
9.61
Pharmaceuticals Industry
- Max
- 8.74
- Q3
- 4.66
- Median
- 2.37
- Q1
- 1.67
- Min
- 0.11
With a P/S Ratio of 9.61, RPRX trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
SYK
5.65
Health Care Equipment & Supplies Industry
- Max
- 9.49
- Q3
- 5.41
- Median
- 2.92
- Q1
- 1.97
- Min
- 0.61
SYK’s P/S Ratio of 5.65 is in the upper echelon for the Health Care Equipment & Supplies industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
RPRX
3.21
Pharmaceuticals Industry
- Max
- 9.86
- Q3
- 5.28
- Median
- 2.48
- Q1
- 1.57
- Min
- 0.59
RPRX’s P/B Ratio of 3.21 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
SYK
6.49
Health Care Equipment & Supplies Industry
- Max
- 10.77
- Q3
- 6.04
- Median
- 3.32
- Q1
- 2.31
- Min
- 0.83
SYK’s P/B Ratio of 6.49 is in the upper tier for the Health Care Equipment & Supplies industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | RPRX | SYK |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 29.52 | 46.83 |
| Price-to-Sales Ratio (TTM) | 9.61 | 5.65 |
| Price-to-Book Ratio (MRQ) | 3.21 | 6.49 |
| Price-to-Free Cash Flow Ratio (TTM) | 18.76 | 33.84 |